Amgen reviews

Incredibly focused on the bottom line, to the detriment of the public health component of the business model. Extremely willing to sell expensive products, particularly to large number of patients, ~90% of whom may not receive benefit over other treatment choices or even no treatment at all, ~10% who may receive a clinical benefit, but also including some who might not experience benefit but do experience clinically significant adverse events. Strong supporter of higher dosages until safety profile precludes further dose increase. Harsh interpersonal environment driven by need to deliver on progress on goal (sell more drug), without significant consideration of societal needs or benefit, beyond that trickling down from incredibly well-compensated management. Positions itself as a benefactor of society, but definitely not the company it used to be, by about 6 times over.

Some district sales managers are better at selling than at managing and should maybe go back to being a sales rep